Encorafenib Combo Boosts PFS in BRAF V600E+ Metastatic Colorectal Cancer

According to topline data from the phase 3 BREAKWATER trial (NCT04607421), the oral small-molecule kinase inhibitor encorafenib (Braftovi) in combination with cetuximab (Erbitux) and FOLFIRI chemotherapy produced significant and clinically meaningful improvement in progression-free survival (PFS) in previously untreated patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation.¹

In the latest trial readout, the encorafenib-based regimen significantly reduced the risk of disease progression or death compared with standard-of-care chemotherapy with or without bevacizumab (Avastin) in cohort 3 (n = 147). Detailed results are expected to be presented at an upcoming medical meeting.

In addition to PFS, the study demonstrated favorable trends in overall survival (OS) with the triplet, another key secondary end point, although these data remain immature at the current analysis. The safety profile of the triplet remained consistent with previously reported data for each individual agent, with no new safety signals identified.

Data presented at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium indicated that the primary end point of objective response rate (ORR) per blinded independent central review was substantially higher with the triplet (64.4% vs 39.2%; OR, 2.76; 95% CI, 1.42-5.35; P = .001), with responses described as more rapid and durable than those seen with traditional chemotherapy.²

“These results build on the positive [ORR] data we recently shared, providing further evidence of the meaningful benefit this [encorafenib]-based targeted approach may offer patients with BRAF V600E–mutant [mCRC],” said Jeff Legos, PhD, MBA, chief oncology officer at Pfizer, in a news release.¹ “The combination of significant responses and now improvement in [PFS] underscores the potential of [encorafenib] as a potentially practice-changing treatment option for patients and families facing this challenging diagnosis.”

The Challenge of BRAF V600E Mutations

The BRAF V600E mutation occurs in approximately 8% to 12% of patients with mCRC and is a notorious biomarker for poor clinical outcomes.³ Historically, these patients have shown limited responsiveness to standard cytotoxic chemotherapy regimens, with median OS often falling below 12 months in the first-line setting.

In December 2024, the FDA granted accelerated approval to encorafenib plus cetuximab and modified FOLFOX6 for the treatment of patients with BRAF V600E–mutant mCRC; this decision was also supported by the BREAKWATER trial.⁴ Additionally, the FDA recently approved the Guardant360 companion diagnostic for use in this patient population to identify those who may benefit from treatment with the triplet.⁵

With detailed data from cohort 3 expected to be shared with the FDA for potential approval of the regimen in this patient population, the latest BREAKWATER findings could further solidify the triplet as a new frontline standard of care for these patients.

About the BREAKWATER Trial

The BREAKWATER study is a global, randomized, multicenter, open-label phase 3 trial that enrolled 831 treatment-naive patients with BRAF V600E–mutant mCRC across different treatment cohorts.⁶ The study was designed to evaluate the efficacy and safety of encorafenib plus cetuximab taken either alone or together with standard chemotherapy.

In cohort 3, a FOLFIRI backbone was explored, with patients randomly assigned 1:1 to receive either the triplet (n = 73) or FOLFIRI with or without bevacizumab (n = 74). Those assigned to the triplet arm have received 300 mg of encorafenib orally once daily with cetuximab and FOLFIRI.

Longer follow-up will determine whether early gains in response and PFS translate into a durable OS advantage and potentially redefine frontline management for this subgroup.

REFERENCES

1. Pfizer’s Braftovi regimen improves progression-free survival in metastatic colorectal cancer. News release. Pfizer. February 17, 2026. Accessed February 17, 2026. https://tinyurl.com/bdcu84ry

2. Kopetz S, Wasan HS, Yoshino T, et al. BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). J Clin Oncol. 2026;44(suppl 2):13. doi:10.1200/jco.2026.44.2_suppl.13

3. Tabernero J, Ros J, Élez E. The evolving treatment landscape in BRAF-V600E–mutated metastatic colorectal cancer. Am Soc Clin Oncol Educ Book. 2022;(42):254-263. doi:10.1200/edbk_349561

4. FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation. FDA. December 20, 2024. Accessed February 17, 2026. https://tinyurl.com/yxnzzp6s

5. Guardant Health receives FDA approval for Guardant360 CDx as companion diagnostic for Braftovi (encorafenib) combination in patients with BRAF V600E-mutant metastatic colorectal cancer. News release. Guardant Health. January 22, 2026. Accessed February 17, 2026. https://tinyurl.com/2e2xrkd6

6. A study of encorafenib plus cetuximab with or without chemotherapy in people with previously untreated metastatic colorectal cancer. ClinicalTrials.gov. Updated August 14, 2025. Accessed February 17, 2026. https://clinicaltrials.gov/study/NCT04607421